Related Experiment Video
Updated: Jul 12, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
The Role of Inflammatory Biomarkers in PIPAC: Predicting Survival and Treatment Completion in Patients with
Signe Roensholdt1,2, Martin Graversen1,3,4, Sönke Detlefsen1,2,5
1Odense PIPAC Center, Odense University Hospital, 5000 Odense, Denmark.
Abstract:
Introduction: Appropriate patient selection is essential for optimising outcomes in individuals with peritoneal metastasis (PM) undergoing treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). This study investigated the prognostic value of pretreatment inflammatory biomarkers and explored their ability to predict the possibility of completion of three or more PIPAC treatments. Method: This observational study analysed prospectively collected data from patients with PM of gastrointestinal or ovarian origin enrolled in the PIPAC OPC-1 or OPC-2 studies between March 2015 and January 2022. Six biomarkers were examined: Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio, Systemic Immune-Inflammation Index (SII), C-reactive protein, modified Glasgow Prognostic Score, and Prognostic Nutritional Index. Biomarkers were obtained pretreatment, and treated as continuous variables. Survival was assessed using Kaplan-Meier and Cox regression analyses, adjusting for covariates available prior to the first PIPAC. ROC analysis was used to evaluate the predictive performance. A p-value less than 0.05 was considered statistically significant. Results: The cohort consisted of 130 patients, with a median overall survival (OS) of 8.7 months. Sixty percent of the patients received three or more PIPAC treatments. Elevated levels of all six biomarkers were significantly associated with reduced OS. In the multivariate analysis, five biomarkers remained independently associated with survival. NLR and SII demonstrated moderate discriminatory power (AUC > 0.70) for predicting the completion of three or more treatments. Conclusion: Pretreatment inflammatory biomarkers are objective, readily accessible and clinically applicable tools that may support the selection of appropriate candidates for PIPAC. The findings of this study encourage the integration of biomarker assessments into future PIPAC research protocols.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...